TTrialPathMatch Me to Trials
← Back to trials
RecruitingType 1 DiabetesOverweight

Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes

Eligible age

21–50 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is: * To see if insulin resistance (how sensitive your muscle tissue is to insulin) is associated with lower cardio fitness in people with Type 1 diabetes compared to healthy controls, before and after a High Intensity Interval Training (HIIT) exercise program. * To see if being overweight and having Type 1 diabetes is associated with lower cardio fitness compared to overweight healthy controls, before and after a HIIT exercise program.

Sponsor: University of Virginia

You may qualify if…

  • ✓ • Male or female ≥21 and ≤50 years old
  • ✓ For persons with T1D: Disease duration ≥ 5 years and HbA1c ≤ 8.5% on multiple daily insulin injection or insulin pump
  • ✓ Body mass index: ≥19 and ≤27 kg/m2 for control and T1D, ≥30 and ≤40 kg/m2 (27.5 to 37.5 for Asian Americans) for obesity and T1D + obesity. BMI is limited to ≤40 kg/m2 (37.5 for Asian Americans) for easier vascular access and cardiac imaging.
  • ✓ Stable use of non-insulin medications for over 6 months other than estrogen/progesterone containing medications which must be discontinued at least 3 months prior to the study (intrauterine devices may be continued due to limited systemic absorption)

You may not qualify if…

  • ✕ • Acute or chronic disease other than T1D or obesity
  • ✕ History of microvascular or macrovascular diabetes complications
  • ✕ History of diabetic ketoacidosis in the past 24 months
  • ✕ History of hypoglycemia unawareness
  • ✕ Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)
  • ✕ Subjects who are smokers or who have quit smoking \<5 years
  • ✕ Subjects with hypertriglyceridemia (\>400 mg/dl)
  • ✕ Current use of vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha- or beta-blockers, or diuretics).

Where it's recruiting

Virginia

Charlottesville

Source: ClinicalTrials.gov · NCT07573228 · last updated 2026-05-07